1. Search Result
Search Result
Results for "

Kv7

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

1

Peptides

1

Recombinant Proteins

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101843

    Potassium Channel Neurological Disease
    ML213 is a selective activator of Kv7.2 and Kv7.4 channels, enhances Kv7.2 and Kv7.4 channels with EC50s of 230 and 510 nM, respectively.
    ML213
  • HY-108577
    XE991 dihydrochloride
    3 Publications Verification

    Potassium Channel Neurological Disease
    XE991 dihydrochloride, a Kv7 (KCNQ) channels blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC50s of 0.75 µM, 0.71 µM, 0.6 μM, and 0.98 µM, respectively .
    XE991 dihydrochloride
  • HY-125469

    PF-04895162

    Potassium Channel Neurological Disease
    ICA-105665 (PF-04895162) is a potent and orally active neuronal Kv7.2/7.3 and Kv7.3/7.5 potassium channels opener. ICA-105665 inhibits liver mitochondrial function and bile salt export protein (BSEP) transport (IC50 of 311 μM). ICA-105665 can penetrate the blood-brain barrier and has antiseizure effects .
    ICA-105665
  • HY-101396
    ICA-069673
    2 Publications Verification

    Potassium Channel Neurological Disease
    ICA-069673 is a KCNQ2/Q3 potassium channel activator. ICA-069673 demonstrates greater selectivity for KV7.2/7.3 over KV7.3/KV7.5, with EC50s of 0.69 μM and 14.3 μM, respectively. ICA-069673 inhibits spontaneous phasic and nerve-evoked contractions in guinea pig detrusor smooth muscle (DSM). ICA-069673 also decreases the global intracellular Ca(2+) concentration in DSM cells .
    ICA-069673
  • HY-164417

    Potassium Channel Neurological Disease
    Kv7.2/Kv7.3 activator-1 (compound 517) is a potent Kv7.2/Kv7.3 channel activator with an EC50 value of <1 µM. Kv7.2/Kv7.3 activator-1 has the potential for the research of neurological diseases .
    Kv7.2/Kv7.3 activator-1
  • HY-168214

    Potassium Channel Neurological Disease
    Kv7.2/Kv7.3 agonist 1 (Compound 16) is an orally active agonist for KV7.2/7.3 channel (KCNQ2/3) with an EC50 of 1.03 μM. Kv7.2/Kv7.3 agonist 1 exhibits analgesic efficacy in mice chronic constriction injury (CCI) model and mice Streptozotocin (HY-13753)-induced diabetic peripheral neuropathic pain (DPNP) model, with ED50 of 12.02 and 9.63 mg/kg .
    Kv7.2/Kv7.3 agonist 1
  • HY-161624

    Potassium Channel Neurological Disease
    Kv7.2 modulator 1 (compound 10) is a Kv7.2 channel modulator and can be used for study of epilepsy .
    Kv7.2 modulator 1
  • HY-161625

    Potassium Channel Neurological Disease
    Kv7.2 modulator 2 (compound 52) is a Kv7.2 channel modulator and can be used for study of epilepsy .
    Kv7.2 modulator 2
  • HY-108577A

    Potassium Channel Neurological Disease
    XE 991 dihydrochloride, a Kv7 (KCNQ) channels blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC50s of 0.75 μM, 0.71 μM, 0.6 μM, and 0.98 μM, respectively .
    XE991
  • HY-159506

    Bimokalnerum

    Potassium Channel Neurological Disease
    Bimokalner (Bimokalnerum) is a voltage-gated potassium channel (Kv7.4) agonist .
    Bimokalner
  • HY-108587

    Potassium Channel Neurological Disease
    ICA 110381 is an orally active Kv7.2/Kv7.3 (KCNQ2/3) potassium channel activator with anticonvulsive properties. ICA 110381 is a KCNQ2/Q3 activator (EC50=0.38 μM) as well as KCNQ1 antagonist (IC50=15 μM) .
    ICA 110381
  • HY-139791

    XEN1101

    Potassium Channel Cancer
    KCNQ2/3 activator-1 is an activator of Kv7.2/Kv7.3 (KCNQ2/3) potassium channel. KCNQ2/3 activator-1 has the potential in relieving pain (the main problem from medical treatment) (extracted from patent WO2021113757A1, compound A) .
    Azetukalner
  • HY-W020468
    Linopirdine
    1 Publications Verification

    DuP 996

    Potassium Channel TRP Channel Neurological Disease
    Linopirdine (DuP 996) is an orally active, selective M-type K + current (IM; Kv7; KCNQ Channels) inhibitor with an IC50 of 2.4 μM. Linopirdine is a TRPV1 agonist. Linopirdine, a putative cognition enhancing agent, increases acetylcholine release in rat brain tissue .
    Linopirdine
  • HY-108590

    XR-543

    Potassium Channel Neurological Disease
    DMP-543 (XR-543) is a KV7 channel blocker, also acts as a potent neurotransmitter release enhancer .
    DMP-543
  • HY-108584

    BMS-204352

    Potassium Channel Neurological Disease
    Flindokalner (BMS-204352) is a potassium channel modulator. Flindokalner is a positive modulator of all neuronal Kv7 channel subtypes expressed in HEK293 cells. Flindokalner is also a large conductance calcium-activated K channel (BKca) positive modulator. Flindokalner shows a negative modulatory activity at Kv7.1 channels (Ki=3.7 μM), and acts as a negative modulator of GABAA receptors. Flindokalner shows anxiolytic efficacy in vivo .
    Flindokalner
  • HY-18063

    Potassium Channel Cytochrome P450 Neurological Disease
    ML252 is a selective inhibitor of KCNQ2 (Kv7.2) channel with an IC50s of 69 nM, 2.92 μM, 0.12 μM and 0.20 μM for KCNQ2, KCNQ1 (Kv7.1), KCNQ2/Q3 and KCNQ4, respectively. ML252 also inhibits Cytochrome P450 with IC50s of 6.1 nM (CYP1A2), 18.9 nM (CYP2C9), 3.9 nM (CYP3A4), 19.9 nM (CYP2D6), respectively. ML252 shows highly brain penetrant .
    ML252
  • HY-18063A

    Potassium Channel Cytochrome P450 Neurological Disease
    ML252 hydrochloride is a selective inhibitor of KCNQ2 (Kv7.2) channel with IC50s of 69 nM, 2.92 μM, 0.12 μM and 0.20 μM for KCNQ2, KCNQ1 (Kv7.1), KCNQ2/Q3 and KCNQ4, respectively. ML252 hydrochloride also inhibits Cytochrome P450 with IC50s of 6.1 nM (CYP1A2), 18.9 nM (CYP2C9), 3.9 nM (CYP3A4), 19.9 nM (CYP2D6), respectively. ML252 hydrochloride shows highly brain penetrant .
    ML252 hydrochloride
  • HY-115823

    Potassium Channel Neurological Disease
    ztz240 is a chemical modulator of voltage-gated potassium channel Kv7 (KCNQ) (KCNQ2 and 3: EC50=6.1 μM; KCNQ4: EC50=12.2 μM). ztz240 can be used in analgesia and anti-epileptic research .
    ztz240
  • HY-108591

    R-L3

    Potassium Channel Cardiovascular Disease
    L-364,373 (R-L3) is a voltage-gated Kv7.1 (KCNQ1)/mink channels activator. L-364,373 activates Iks (slow delayed rectifier potassium current) and shortens action potential duration in guinea pig cardiac myocytes, and suppresses early afterdepolarizations in rabbit ventricular myocytes .
    L-364,373
  • HY-110162

    Potassium Channel Neurological Disease
    QO 58 is a potent modulator of K(v)7 channels. QO-58 increases the current amplitudes, shifts the voltage-dependent activation curve in a more negative direction and slows the deactivation of K(v)7.2/K(v)7.3 currents. QO-58 has the potential for the research of diseases associated with neuronal hyperexcitability .
    QO 58
  • HY-P5925

    SsTx Toxin

    Potassium Channel Inflammation/Immunology
    Ssm Spooky Toxin from?Scolopendra mutilans, exhibits lethal toxicity in hematological and respiratory systems by potently inhibiting KCNQ (voltage-gated potassium channel family 7) channels, with IC50? of 2.8 μM, 5.26 μM and 0.1-0.3 M for Kv7.4, Kv1.3, and Shal channel, respectivily. Ssm Spooky Toxin inhibits cytokine generation by specifically acting on the KV1.3 channel in T cells. Ssm Spooky Toxin plays an essential role in the centipede’s circulatory system .
    Ssm spooky toxin
  • HY-145016

    Potassium Channel Neurological Disease
    HN37 as a potent and chemically stable antiepileptic agent candidate, with an EC50 of 37 nM for KCNQ2 .
    HN37

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: